Naratuximab emtansine

DB15453InvestigationalProtein Based Therapies

Naratuximab emtansine is under investigation in clinical trial NCT01534715 (IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia).

Mechanism: Pharmacologically active on Leukocyte antigen CD37
Curator reviewed
Code names: IMGN529

Resolves to

Compound

UNIIWE1X5A83B9CAS1607824-64-5

Targets

P11049CD37

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

1Clinical trialPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Naratuximab emtansine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account